Youko Suehiro
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Utility of Flow Cytometry for Prognostic Prediction in Adult T-Cell Leukemia/Lymphoma.
Journal: EJHaem
Published: January 21, 2026
Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma.
Journal: Hematological oncology
Published: October 13, 2025
Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.
Journal: British journal of haematology
Published: October 08, 2025
Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
Journal: Cancer science
Published: August 26, 2025
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.
Journal: International journal of hematology
Published: July 28, 2025
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
Journal: Leukemia & lymphoma
Published: July 09, 2025
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Adult T-Cell Leukemia/Lymphoma: A Nationwide Retrospective Study.
Journal: Transplantation and cellular therapy
Published: June 28, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.
Journal: Japanese journal of clinical oncology
Published: May 07, 2025
Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Journal: Internal medicine (Tokyo, Japan)
Published: April 13, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Journal: International journal of clinical oncology
Published: March 13, 2025
Last Updated: 09/26/2026